Interestingly, BRG1 binding in the AML cell lines EOL1 and MOLM13 presents with higher enrichment at AMLgained CTCF sites than at constitutive CTCF sites (P < 1e−66) (Fig. 6d, Additional file 1: Fig. S16a) [59], although CTCF itself has lower binding levels at their corresponding gained sites in both AML and T-ALL than at constitutive sites (P = 0 for AML; P = 4.4e−9 for T-ALL) (Fig. 6e, Additional file 1: Fig. S16b,c), suggesting that BRG1 might preferentially localize to gained CTCF sites. The gene discussed is CTCF; the disease is acute lymphoblastic leukemia.